STAT3 and pancreatic neoplasm: Additionally, PPAR-γ and its agonists in combination with other drugs—such as type I interferons, gemcitabine, and COX-2 inhibitors—inhibit the survival of pancreatic cancer cells via IFN-β-induced activation of STAT-3, MAPK, and AKT [137,138].